GH Research (NASDAQ:GHRS) Trading 8.3% Higher – What’s Next?

Shares of GH Research PLC (NASDAQ:GHRS) were up 8.3% during trading on Monday . The stock traded as high as $13.50 and last traded at $13.54. Approximately 95,516 shares were traded during trading, a decline of 48% from the average daily volume of 184,688 shares. The stock had previously closed at $12.50.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on GHRS shares. Royal Bank of Canada assumed coverage on GH Research in a research note on Friday, March 7th. They issued an “outperform” rating and a $31.00 target price for the company. Stifel Nicolaus upped their price target on GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Friday, May 9th. Cantor Fitzgerald initiated coverage on shares of GH Research in a research report on Wednesday, June 4th. They issued an “overweight” rating and a $25.00 price target for the company. Finally, Wall Street Zen downgraded shares of GH Research from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, GH Research presently has an average rating of “Moderate Buy” and an average price target of $32.00.

GH Research Stock Up 9.0%

The stock has a market cap of $708.62 million, a price-to-earnings ratio of -17.26 and a beta of 0.97. The company’s 50-day simple moving average is $10.39 and its 200-day simple moving average is $10.25.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.42. As a group, analysts expect that GH Research PLC will post -0.8 EPS for the current fiscal year.

Institutional Trading of GH Research

A number of large investors have recently bought and sold shares of GHRS. BNP Paribas Financial Markets acquired a new stake in shares of GH Research in the fourth quarter valued at approximately $44,000. Northern Trust Corp raised its holdings in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after acquiring an additional 8,641 shares during the period. Woodline Partners LP grew its holdings in shares of GH Research by 112.0% during the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock worth $553,000 after buying an additional 41,711 shares in the last quarter. Lynx1 Capital Management LP grew its stake in shares of GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after acquiring an additional 663,100 shares in the last quarter. Finally, Diadema Partners LP bought a new stake in GH Research during the 4th quarter worth about $711,000. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).